ALSO NOTED: Sepracor expands HQ; Sanofi profits jump 9.1 percent;

> Sepracor's layoffs weren't the only news to come out of its earnings announcement yesterday; the company also will expand its Boston-area offices with a 150,000-square-foot building next to HQ. Report

> Sanofi-Aventis reported a 9.1 percent spike in profits on strong sales of vaccines and its anti-clotting drug Plavix. Report

> Novo Nordisk reported a leap in third-quarter profits to $421 million, but lowered its full-year sales expectations because of currency exchange rates. Report

> Nycomed is buying Bradley Pharmaceuticals for $346 million cash, or $20 a share. Report

> India's Glenmark Pharmaceuticals posted profits of $18.4 million on revenues of $93.8 million for the quarter--growth of 50 percent and 88 percent respectively. Report

> Scientists at Brookhaven National Laboratory have added to the store of knowledge linking dopamine to obesity. Report

> Sangamo shares leap on stem cell tech advance. Report

> Researchers at the University of Cincinnati have identified a new target for drug developers out to control obesity and diabetes. Report

And Finally… Here's one reason to wear pajamas when you're on the road--or develop a new sleeping pill back home: an epidemic of sleepwalking through hotel lobbies. Report

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.